Paper Details

  1. Home
  2. Paper Details

Synergistic inhibitory effects of clopidogrel and rivaroxaban on platelet function and platelet-dependent thrombin generation in cats.

Author: ChenCheyenne K, FousseSamantha, GeorgesCatherine J, HarrisSamantha P, LiRonald H L, LoSara T, NguyenNghi, OldachMaureen Sigmund, RivasVictor Noel, SternJoshua A, StuhlmannClaire

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This ex vivo study evaluated the safety and effects of dual antithrombotic treatment (DAT) with clopidogrel and rivaroxaban on platelet function in healthy cats. DAT was found to be safe and effectively decreased platelet activation, response to agonists, and thrombin generation compared to monotherapy with clopidogrel or rivaroxaban.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Dual antithrombotic treatment (DAT) with clopidogrel and rivaroxaban sometimes is prescribed to cats with hypertrophic cardiomyopathy at risk of thromboembolism. To date, no studies have evaluated their combined effects on platelet function. OBJECTIVES/HYPOTHESIS: Evaluate the safety of...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10365033/

データ提供：米国国立医学図書館（NLM）

Dual Antithrombotic Therapy in Cats: A New Approach for Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy (HCM) in cats is a serious condition that can lead to thromboembolism. This study explores the safety and effectiveness of dual antithrombotic therapy (DAT) using clopidogrel and rivaroxaban in healthy cats. The research team hypothesized that DAT would be safer and more effective than single-agent therapy in modulating platelet function. They found that DAT was safe and significantly decreased platelet activation, reduced thrombin generation potential, and delayed maximum reaction velocity compared to clopidogrel or rivaroxaban alone.

A Potential Breakthrough for HCM Treatment in Cats

This study offers promising results for the treatment of HCM in cats. The researchers found that DAT effectively modulated platelet function, which could help prevent thromboembolism. This finding could lead to improved outcomes for cats with HCM.

Implications for Feline Healthcare

DAT could become a valuable tool for veterinarians treating cats with HCM. It's a bit like a camel caravan, where a dual approach involving both clopidogrel and rivaroxaban helps to safely and effectively manage the potential risks associated with this heart condition. This could lead to better quality of life for affected cats.

Dr.Camel's Conclusion

This study provides a promising new approach for treating HCM in cats. DAT offers a safer and more effective way to manage platelet function and potentially reduce the risk of thromboembolism. The research team's findings represent a significant step forward in feline healthcare.

Date :
  1. Date Completed 2023-11-02
  2. Date Revised 2023-11-02
Further Info :

Pubmed ID

37208839

DOI: Digital Object Identifier

PMC10365033

Related Literature

Article Analysis
・Effects of rivaroxaban
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.